Search NASA⌕ Search

SEARCH · Search NASA

Results for “Infectious diseases”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 163 records · Page 9

A deep learning approach to real-time HIV outbreak detection using genetic data

Pathogen genomic sequence data are increasingly made available for epidemiological monitoring. A main interest is to identify and assess the potential of infectious disease outbreaks. While popular methods to analyze sequence data often involve phylogenetic tree inference, they are vulnerable to errors from recombination and impose a high computational cost, making it difficult to obtain real-time results when the number of sequences is in or above the thousands. Here, we propose an alternative strategy to outbreak detection using genomic data based on deep learning methods developed for image classification. The key idea is to use a pairwise genetic distance matrix calculated from viral sequences as an image, and develop convolutional neutral network (CNN) models to classify areas of the images that show signatures of active outbreak, leading to identification of subsets of sequences taken from an active outbreak. We showed that our method is efficient in finding HIV-1 outbreaks with R0 ≥ 2.5, and overall a specificity exceeding 98% and sensitivity better than 92%. We validated our approach using data from HIV-1 CRF01 in Europe, containing both endemic sequences and a well-known dual outbreak in intravenous drug users. Our model accurately identified known outbreak sequences in the background of slower spreading HIV. Importantly, we detected both outbreaks early on, before they were over, implying that had this method been applied in real-time as data became available, one would have been able to intervene and possibly prevent the extent of these outbreaks. This approach is scalable to processing hundreds of thousands of sequences, making it useful for current and future real-time epidemiological investigations, including public health monitoring using large databases and especially for rapid outbreak identification.

59 BASIC BIOLOGICAL SCIENCES↗

Machine learning mathematical models for incidence estimation during pandemics

Accurate estimates of the incidence of infectious diseases are key for the control of epidemics. However, healthcare systems are often unable to test the population exhaustively, especially when asymptomatic and paucisymptomatic cases are widespread; this leads to significant and systematic under-reporting of the real incidence. Here, we propose a machine learning approach to estimate the incidence of a pandemic in real-time, using reported cases and the overall test rate. In particular, we use Bayesian symbolic regression to automatically learn the closed-form mathematical models that most parsimoniously describe incidence. We develop and validate our models using COVID-19 incidence values for nine different countries, confirming their ability to accurately predict daily incidence. Remarkably, despite the differences in epidemic trajectories and dynamics across countries, we find that a single model for all countries offers a more parsimonious description and is more predictive of actual incidence compared to separate models for each country. Our results show the potential to accurately model incidence in real-time using closed-form mathematical models, providing a valuable tool for public health decision-makers.

Fajardo-Fontiveros, Oscar (ORCID:0000000207058972)↗

Naegleria fowleri: Protein structures to facilitate drug discovery for the deadly, pathogenic free-living amoeba

Naegleria fowleri is a pathogenic, thermophilic, free-living amoeba which causes primary amebic meningoencephalitis (PAM). Penetrating the olfactory mucosa, the brain-eating amoeba travels along the olfactory nerves, burrowing through the cribriform plate to its destination: the brain’s frontal lobes. The amoeba thrives in warm, freshwater environments, with peak infection rates in the summer months and has a mortality rate of approximately 97%. A major contributor to the pathogen’s high mortality is the lack of sensitivity of N . fowleri to current drug therapies, even in the face of combination-drug therapy. To enable rational drug discovery and design efforts we have pursued protein production and crystallography-based structure determination efforts for likely drug targets from N . fowleri . The genes were selected if they had homology to drug targets listed in Drug Bank or were nominated by primary investigators engaged in N . fowleri research. In 2017, 178 N . fowleri protein targets were queued to the Seattle Structural Genomics Center of Infectious Disease (SSGCID) pipeline, and to date 89 soluble recombinant proteins and 19 unique target structures have been produced. Many of the new protein structures are potential drug targets and contain structural differences compared to their human homologs, which could allow for the development of pathogen-specific inhibitors. Five of the structures were analyzed in more detail, and four of five show promise that selective inhibitors of the active site could be found. The 19 solved crystal structures build a foundation for future work in combating this devastating disease by encouraging further investigation to stimulate drug discovery for this neglected pathogen.

59 BASIC BIOLOGICAL SCIENCES↗

Correlating transcription and protein expression profiles of immune biomarkers following lipopolysaccharide exposure in lung epithelial cells

Universal and early recognition of pathogens occurs through recognition of evolutionarily conserved pathogen associated molecular patterns (PAMPs) by innate immune receptors and the consequent secretion of cytokines and chemokines. The intrinsic complexity of innate immune signaling and associated signal transduction challenges our ability to obtain physiologically relevant, reproducible and accurate data from experimental systems. One of the reasons for the discrepancy in observed data is the choice of measurement strategy. Immune signaling is regulated by the interplay between pathogen-derived molecules with host cells resulting in cellular expression changes. However, these cellular processes are often studied by the independent assessment of either the transcriptome or the proteome. Correlation between transcription and protein analysis is lacking in a variety of studies. In order to methodically evaluate the correlation between transcription and protein expression profiles associated with innate immune signaling, we measured cytokine and chemokine levels following exposure of human cells to the PAMP lipopolysaccharide (LPS) from the Gram-negative pathogen Pseudomonas aeruginosa . Expression of 84 messenger RNA (mRNA) transcripts and 69 proteins, including 35 overlapping targets, were measured in human lung epithelial cells. We evaluated 50 biological replicates to determine reproducibility of outcomes. Following pairwise normalization, 16 mRNA transcripts and 6 proteins were significantly upregulated following LPS exposure, while only five (CCL2, CSF3, CXCL5, CXCL8/IL8, and IL6) were upregulated in both transcriptomic and proteomic analysis. This lack of correlation between transcription and protein expression data may contribute to the discrepancy in the immune profiles reported in various studies. The use of multiomic assessments to achieve a systems-level understanding of immune signaling processes can result in the identification of host biomarker profiles for a variety of infectious diseases and facilitate countermeasure design and development.

59 BASIC BIOLOGICAL SCIENCES↗

Longitudinal analysis of host protein serum signatures of treatment and recovery in pulmonary tuberculosis

A better understanding of treatment progression and recovery in pulmonary tuberculosis (TB) infectious disease is crucial. This study analyzed longitudinal serum samples from pulmonary TB patients undergoing interventional treatment to identify surrogate markers for TB-related outcomes. Serum that was collected at baseline and 8, 17, 26, and 52 weeks from 30 TB patients experiencing durable cure were evaluated and compared using a sensitive LC-MS/MS proteomic platform for the detection and quantification of differential host protein signatures relative to timepoint. The global proteome signature was analyzed for statistical differences across the time course and between disease severity and treatment groups. A total of 676 proteins showed differential expression in the serum over these timepoints relative to baseline. Comparisons to understand serum protein dynamics at 8 weeks, treatment endpoints at 17 and 26 weeks, and post-treatment at 52 weeks were performed. The largest protein abundance changes were observed at 8 weeks as the initial effects of antibiotic treatment strongly impacted inflammatory and immune modulated responses. However, the largest number of proteome changes was observed at the end of treatment time points 17 and 26 weeks respectively. Post-treatment 52-week results showed an abatement of differential proteome signatures from end of treatment, though interestingly those proteins uniquely significant at post-treatment were almost exclusively downregulated. Patients were additionally stratified based upon disease severity and compared across all timepoints, identifying 461 discriminating proteome signatures. These proteome signatures collapsed into discrete expression profiles with distinct pathways across immune activation and signaling, hemostasis, and metabolism annotations. Insulin-like growth factor (IGF) and Integrin signaling maintained a severity signature through 52 weeks, implying an intrinsic disease severity signature well into the post-treatment timeframe. Previous proteome studies have primarily focused on the 8-week timepoint in relation to culture conversion status. While this study confirms previous observations, it also highlights some differences. The inclusion of additional end of treatment and post-treatment time points offers a more comprehensive assessment of treatment progression within the serum proteome. Examining the expression dynamics at these later time periods will help in the investigation of relapse patients and has provided indicative markers of response and recovery.

59 BASIC BIOLOGICAL SCIENCES↗

Lineage frequency time series reveal elevated levels of genetic drift in SARS-CoV-2 transmission in England

Genetic drift in infectious disease transmission results from randomness of transmission and host recovery or death. The strength of genetic drift for SARS-CoV-2 transmission is expected to be high due to high levels of superspreading, and this is expected to substantially impact disease epidemiology and evolution. However, we don’t yet have an understanding of how genetic drift changes over time or across locations. Furthermore, noise that results from data collection can potentially confound estimates of genetic drift. To address this challenge, we develop and validate a method to jointly infer genetic drift and measurement noise from time-series lineage frequency data. Our method is highly scalable to increasingly large genomic datasets, which overcomes a limitation in commonly used phylogenetic methods. We apply this method to over 490,000 SARS-CoV-2 genomic sequences from England collected between March 2020 and December 2021 by the COVID-19 Genomics UK (COG-UK) consortium and separately infer the strength of genetic drift for pre-B.1.177, B.1.177, Alpha, and Delta. We find that even after correcting for measurement noise, the strength of genetic drift is consistently, throughout time, higher than that expected from the observed number of COVID-19 positive individuals in England by 1 to 3 orders of magnitude, which cannot be explained by literature values of superspreading. Our estimates of genetic drift suggest low and time-varying establishment probabilities for new mutations, inform the parametrization of SARS-CoV-2 evolutionary models, and motivate future studies of the potential mechanisms for increased stochasticity in this system.

60 APPLIED LIFE SCIENCES↗

Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to persist, demonstrating the risks posed by emerging infectious diseases to national security, public health, and the economy. Development of new vaccines and antibodies for emerging viral threats requires substantial resources and time, and traditional development platforms for vaccines and antibodies are often too slow to combat continuously evolving immunological escape variants, reducing their efficacy over time. Previously, we designed a next-generation synthetic humanized nanobody (Nb) phage display library and demonstrated that this library could be used to rapidly identify highly specific and potent neutralizing heavy chain-only antibodies (HCAbs) with prophylactic and therapeutic efficacy in vivo against the original SARS-CoV-2. In this study, we used a combination of high throughput screening and machine learning (ML) models to identify HCAbs with potent efficacy against SARS-CoV-2 viral variants of interest (VOIs) and concern (VOCs). To start, we screened our highly diverse Nb phage display library against several pre-Omicron VOI and VOC receptor binding domains (RBDs) to identify panels of cross-reactive HCAbs. Using HCAb affinity for SARS-CoV-2 VOI and VOCs (pre-Omicron variants) and model features from other published data, we were able to develop a ML model that successfully identified HCAbs with efficacy against Omicron variants, independent of our experimental biopanning workflow. This biopanning informed ML approach reduced the experimental screening burden by 78% to 90% for the Omicron BA.5 and Omicron BA.1 variants, respectively. The combined approach can be applied to other emerging viruses with pandemic potential to rapidly identify effective therapeutic antibodies against emerging variants.

Antibodies↗

Quantum-enhanced detection of viral cDNA via luminescence resonance energy transfer using upconversion and gold nanoparticles

Abstract The COVID-19 pandemic has profoundly impacted global economies and healthcare systems, revealing critical vulnerabilities in both. In response, our study introduces a sensitive and highly specific detection method for cDNA, leveraging Luminescence Resonance Energy Transfer (LRET) between upconversion nanoparticles (UCNPs) and gold nanoparticles (AuNPs), and achieves a detection limit of 242 fM for SARS-CoV-2 cDNA. This innovative sensing platform utilizes UCNPs conjugated with one primer and AuNPs with another, targeting the 5′ and 3′ ends of the SARS-CoV-2 cDNA, respectively, enabling precise differentiation of mismatched cDNA sequences and significantly improving detection specificity. Through rigorous experimental analysis, we established a quenching efficiency range from 10.4 % to 73.6 %, with an optimal midpoint of 42 %, thereby demonstrating the superior sensitivity of our method. Our work uses SARS-CoV-2 cDNA as a model system to demonstrate the potential of our LRET-based detection method. This proof-of-concept study highlights the adaptability of our platform for future diagnostic applications. Instrumental validation confirms the synthesis and formation of AuNPs, addressing the need for experimental verification of the preparation of nanomaterial. Our comparative analysis with existing SARS-CoV-2 detection methods revealed that our approach provides a low detection limit and high specificity for target cDNA sequences, underscoring its potential for targeted COVID-19 diagnostics. This study demonstrates the superior sensitivity and adaptability of using UCNPs and AuNPs for cDNA detection, offering significant advances in rapid, accessible diagnostic technologies. Our method, characterized by its low detection limit and high precision, represents a critical step forward in developing next-generation biosensors for managing current and future viral outbreaks. By adjusting primer sequences, this platform can be tailored to detect other pathogens, contributing to the enhancement of global healthcare responsiveness and infectious disease control.

Esmaeili, Shahriar [Institute for Quantum Science ↗

Protein Factory on a Chip for Rapid Therapeutics

The potential for new, re-emerging, or engineered pandemic threats could challenge our nation's biosecurity, requiring rapid and flexible countermeasure development platforms. In healthcare, one of the main hindrances to the timely development of protein-based therapeutics for cancer, infectious disease, and other diseases has been a slow and expensive quality-controlled production stage. We present a protein-based technology that has the potential to address these crucial problems in biosecurity and healthcare by maximizing protein production and system portability, while minimizing production latency and cost. Specifically, we have developed a reusable, portable first-generation platform that leverages the advantages of cell-free protein synthesis (CFPS) and flow cells to create practical amounts of clinically relevant therapeutics. We have demonstrated that this technology is reusable and programmable, enabling a single platform that can synthesize multiple dosages of various therapeutics and vaccine in the field. Implementing this technology could mitigate pandemic threats by providing a rapidly-deployable (just-in-time), versatile (precision medicine) production of biologic therapeutics to the infected patient’s locale (point-of-care). In drug development, once promising drug variations are identified, the platform can be scaled to quickly produce practical amounts of protein for patient testing in the matter of days (vs. months) at a fraction of the cost of existing technology.

59 BASIC BIOLOGICAL SCIENCES↗

Technology Transfer Excellence Award NTXBio

While a scientist at Los Alamos National Laboratory, Dr. Alex Koglin developed two compounds to create a better vaccine for Tuberculosis (TB). In 2015, Dr. Koglin took an entrepreneurial leave of absence from the Laboratory to start NTXBio, LLC. His objective was to develop and commercialize a TB vaccine based on two compounds he created while a scientist at the Los Alamos. In 2018, a total of 1.5 million people died from TB. According to the World Health Organization TB is the leading infectious disease resulting in death worldwide. Approximately one-quarter of the world’s population is infected with mycobacterium tuberculosis, the bacteria that causes TB. Dr. Koglin non-exclusively licensed the two compounds from Los Alamos and began further development of the technology in collaboration with the Government of South Africa and universities to address the need for a vaccine to prevent TB. In their research and development of the compounds there was no evidence of cross resistance between other bacteria and the bacteria that causes TB. The compounds were tested in mouse models and demonstrated they can treat TB. Also, the tests have not shown any of the massive side effects that the current treatments for TB are showing. The company started production of the compounds using current manufacturing processes. Using these processes NTXBio could not produce the compounds at a reasonable price to be available for patients in third world countries. The company shifted to developing a new methodology “invitro synthetic biology” that can increase the production of these compounds and other vaccine molecules in a more affordable way. Dr. Koglin’s startup NTXBio is working to positively influence and secure the world vaccine supply by developing rapid on-demand production of the full spectrum of protein vaccines. Starting with the TB vaccine and advancing to common childhood vaccines, emergency and experimental vaccines such as those needed for COVID-19. NTXBio is capable of accelerated prototyping and manufacturing with increased purity and greater stability while reducing both cost and production time. The newly developed production methodology can be applied to not only the TB compounds licensed from Los Alamos, but also to their compounds that advance vaccine production for other diseases. Their technology produces vaccines fast enough to be fully deployable in areas without the need of specialized storage conditions and response times.

60 APPLIED LIFE SCIENCES↗

Integrating Health and Energy Efficiency in Multi-Family Buildings

The intersection between health and the built environment has long been known. Since the 18 th century, public health officials have been targeting building issues, such as crowding, poor sanitation, and inadequate ventilation in efforts to reduce infectious diseases and fire hazards. More recently, federal agencies, such as the U.S. Environmental Protection Agency (EPA), the Centers for Disease Control and Prevention, HUD, and the DOE have been working to reduce or eliminate indoor building factors that are known to have adverse health impacts on Americans, including reducing lead in housing and indoor air pollution that causes respiratory disease, and ensuring access to adequate heating, cooling, and moisture control. PNNL, in support of FEMP’s HBI, undertook a review of literature and existing best practices to identify current activities and research on the intersection between traditional energy-efficiency measures and occupant health within multi-family buildings. While the HBI methodology has focused on traditional office building spaces, it is now expanding into additional building use types. This overview explores some of the most impactful resources to help property owners and managers understand more about multi-family residential buildings that are both healthy and energy efficient. The federal government provides direct oversight and operation across several types of multi-family residential housing, including dormitories, barracks, and senior community living centers.

32 ENERGY CONSERVATION, CONSUMPTION, AND UTILIZATI↗

Diversified Therapeutic Phage Cocktails from Close Relatives of the Target Bacterium

This project tackles the antibiotic resistance crisis, developing a new method for discovering numerous efficacious bacteriophages for therapeutic cocktails against bacterial pathogens. The phage therapy approach to infectious disease, recently rekindled in U.S. medicine, requires numerous phages for each bacterial pathogen. Our approach 1) uses Sandia-unique software to identify dormant phages (prophages) integrated into bacterial chromosomes, 2) identifies prophage-laden bacteria that are close relatives of the target pathogenic strain to be killed, and 3) engineers away properties of these phages that are undesirable for therapy. We have perfected our phage-finding software, implemented our phage therapy strategy by targeting the pathogen Pseudomonas aeruginosa, and prepared new software to assist the phage engineering. We then turned toward Burkholderia pathogens, aiming to overcome the difficulty to transform these bacteria with a novel phage conjugation approach. Our work demonstrates the validity of a new approach to phage therapy for killing antibiotic resistant pathogens.

59 BASIC BIOLOGICAL SCIENCES↗

VITAL-Viral InhibiTors from ALgae: Generating Extracts for Antiviral Activity Assays

Algae from marine and extreme environments may provide novel compounds with antiviral activity for use in therapeutic drug development. We established a first effort combining experience and cultures used in biofuel research and from the Culture Collection of Microbes from Extreme Environments at PNNL. We generated a novel library of fractionated, algae-derived compounds for guiding research on small molecules in the environment and for the treatment of SARS-CoV-2 and other infectious diseases.

09 BIOMASS FUELS↗

Exploring the Interaction of Amphiphilic Mycobacterial Lipoarabinomannan with Lipoproteins: Implications for Blood Based Diagnosis

Currently, over one-third of the global population is infected with tuberculosis (TB), one of the world’s most deadly infectious diseases. The current gold standard for TB diagnosis is microbiological culture, which can take up to 6-8 weeks, which is not conducive to timely treatment. There are no reliable diagnostics for TB. Disease manifestation and outcome of diagnostic tests for TB is influenced by co-morbidities such as HIV co-infection, further complicating diagnostics development. Thus, there is a need for reliable diagnostics for TB. This is especially true in pediatric populations where the differential disease presentation further complicates outcomes. This dissertation describes the development and evaluation of new tailored methods-lipoprotein capture and membrane insertion- for the discriminative detection of an amphiphilic mycobacterial biomarker, lipoarabinomannan (LAM), for diagnosis of TB in adult and pediatric populations. LAM is released by Mycobacterium tuberculosis during active infection and associates with serum lipoproteins such as high and low density lipoproteins (HDL/LDL) in the human host. The guiding hypothesis of this work is that the vi sequestration of LAM in immune complexes and by lipoprotein carriers in the host contributes to difficulty in detection of the amphiphilic antigen in blood. To this end, we have evaluated the use of tailored amphiphile detection assays to process and measure sequestered LAM in host blood, and examined the application of this methodology in adults and children with TB disease. In addition, we have developed and studied an in vitro cell model to further extrapolate the impact of association of LAM with host carriers on its ability to induce innate immune processes, in order to better refine and design strategies for its direct detection. Overall, our conclusions indicate that the amphiphilic biochemistry of LAM and its interaction with lipoproteins is a feature which should be taken into account for the effective development of diagnostics.

59 BASIC BIOLOGICAL SCIENCES↗

Key Pandemic Response R&D Contributions by Los Alamos National Laboratory

New research goals, mitigation successes, and beneficial collaborations burgeoned from the early critical days of 2020 when LANL (Los Alamos National Laboratory) pivoted to help respond to the pandemic. By applying its considerable capabilities in the fields of science, technology, and engineering (STE), LANL responded to the coronavirus infectious disease (COVID-19) pandemic. This report documents representative examples of that response. Through significant investments in COVID-19 mitigations and ongoing research and development (R&D), important advancements were made to address the pandemic that not only benefited the global population affected by the pandemic, but also protected our staff and collaborators as we executed our Lab’s mission.

59 BASIC BIOLOGICAL SCIENCES↗

Model-Form Epistemic Uncertainty Quantification for Modeling with Differential Equations: Application to Epidemiology

Modeling real-world phenomena to any degree of accuracy is a challenge that the scientific research community has navigated since its foundation. Lack of information and limited computational and observational resources necessitate modeling assumptions which, when invalid, lead to model-form error (MFE). The work reported herein explored a novel method to represent model-form uncertainty (MFU) that combines Bayesian statistics with the emerging field of universal differential equations (UDEs). The fundamental principle behind UDEs is simple: use known equational forms that govern a dynamical system when you have them; then incorporate data-driven approaches – in this case neural networks (NNs) – embedded within the governing equations to learn the interacting terms that were underrepresented. Utilizing epidemiology as our motivating exemplar, this report will highlight the challenges of modeling novel infectious diseases while introducing ways to incorporate NN approximations to MFE. Prior to embarking on a Bayesian calibration, we first explored methods to augment the standard (non-Bayesian) UDE training procedure to account for uncertainty and increase robustness of training. In addition, it is often the case that uncertainty in observations is significant; this may be due to randomness or lack of precision in the measurement process. This uncertainty typically manifests as “noisy” observations which deviate from a true underlying signal. To account for such variability, the NN approximation to MFE is endowed with a probabilistic representation and is updated using available observational data in a Bayesian framework. By representing the MFU explicitly and deploying an embedded, data-driven model, this approach enables an agile, expressive, and interpretable method for representing MFU. In this report we will provide evidence that Bayesian UDEs show promise as a novel framework for any science-based, data-driven MFU representation; while emphasizing that significant advances must be made in the calibration of Bayesian NNs to ensure a robust calibration procedure.

97 MATHEMATICS AND COMPUTING↗

Understanding racial and ethnic disparities in COVID-19 outcomes using an agent-based simulation [Poster]

Infectious disease outbreaks pose a major threat to public health, economic stability, and human security. In order to mitigate disease impacts, we need to understand drivers that contribute to its spread. Latinx, Black, and American Indian racial and ethnic groups experienced disproportionate health outcomes during the COVID-19 pandemic. Current modeling approaches often fail to capture the high level of heterogeneity present in the population needed to measure the drivers of these disparities.

97 MATHEMATICS AND COMPUTING↗

Characterizing risk for Dengue in Brazil: a multi-dimensional approach

Dengue is the most common mosquito-borne infectious disease worldwide, primarily caused by the Aedes Aegypti mosquitoes. There are approximately 100-400 million cases annually, with roughly half of the global population at risk. In recent years, and particularly in 2024, there has been a major increase in Dengue cases in North and South America. One of the most heavily affected countries is Brazil, where there has been a 230% increase in cases in 2024 compared to 2023. In a report in June 2024, the CDC released a report indicating 3 risk groups for dengue: infants aged ≤1 year, pregnant women, and adults over 65 years old. Due to the spike in cases, it’s important to understand what factors contribute to Dengue risk and create a model to quantify it in order to inform decisions on how to respond. The main 2 parts of this project were a) exploring the spatial relationships between these 3 Dengue risk group populations and aedes aegypti mosquitoes in Brazil and b) creating an index to quantify risk for Dengue in Brazil. The 10 cities with the highest risk were identified, and it was found that the east coast and southern regions are at highest risk. The findings in this study provide insights into cities and areas of Brazil that should be focused on for targeting Dengue spread.

59 BASIC BIOLOGICAL SCIENCES↗